- Conditions
- Uveitis Posterior Non-Infectious, Uveitis, Intermediate, Noninfectious Panuveitis
- Interventions
- ESK-001
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 17
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 354
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Choroidal Neovascularization
- Interventions
- Faricimab, Ranibizumab, Sham Procedure
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- ADX-038, Placebo
- Drug
- Lead sponsor
- ADARx Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 21
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 18 more
- Conditions
- Dry Eye Syndromes
- Interventions
- ADX-102 Ophthalmic Solution (0.5%), ADX-102 Ophthalmic Solution (0.1%), ADX-102 Ophthalmic Lipid Solution (0.5%)
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Age-Related Macular Degeneration
- Interventions
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more
- Conditions
- Stargardt Disease
- Interventions
- ALK-001, Placebo
- Drug
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 11 more
- Conditions
- Vitreoretinal Traction Syndrome
- Interventions
- Plasmin, Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
- Interventions
- Linsitinib, Placebo
- Drug
- Lead sponsor
- Sling Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 19
- States / cities
- Beverly Hills, California • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Neovascular Age-related Macular Degeneration, nAMD
- Interventions
- ABP 938 8 mg, Aflibercept (US) 8 mg
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 55
- States / cities
- Fullerton, California • Long Beach, California • Modesto, California + 50 more
- Conditions
- Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders
- Interventions
- QR-1123, Sham procedure
- Drug · Other
- Lead sponsor
- ProQR Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Gainesville, Florida • Lexington, Kentucky + 2 more
- Conditions
- Health Behavior, Health Care Utilization
- Interventions
- Phase II Promotores de Salud, Phase I Promotores de Salud Outreach
- Behavioral
- Lead sponsor
- University of Oregon
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 1,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Geographic Atrophy
- Interventions
- Danicopan, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 45 more
- Conditions
- Surgery
- Interventions
- BlockSynop surface electromyography device, Clonidine, Sevoflurane
- Device · Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 0 Years to 5 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 55
- States / cities
- Mesa, Arizona • Sun City, Arizona • Campbell, California + 51 more
- Conditions
- Anesthesia, Local
- Interventions
- AG-920, Placebo
- Drug
- Lead sponsor
- American Genomics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- McAllen, Texas
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial), NCX 470 0.1% (remainder of trial), Latanoprost 0.005% (remainder of trial)
- Drug
- Lead sponsor
- Nicox Ophthalmics, Inc.
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Blepharitis
- Interventions
- Moxidectin 2 MG Oral Tablet, Placebo
- Drug
- Lead sponsor
- Eye Research Foundation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Interventions
- LKA651, Sham Comparator
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 5
- States / cities
- Pasadena, California • Fort Myers, Florida • Miami, Florida + 2 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- R89674 0.025% ophthalmic solution
- Drug
- Lead sponsor
- Vistakon Pharmaceuticals
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • North Andover, Massachusetts • Creve Coeur, Missouri + 3 more
- Conditions
- Mask Ventilation, Airway Obstruction Upper, Airway Management
- Interventions
- Articulated Oral Airway, Guedel oral airway (active comparator)
- Device
- Lead sponsor
- Ron Abrons
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Non-Infectious Uveitis
- Interventions
- FAI insert, Sham injection
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Sacramento, California • Torrance, California + 13 more
- Conditions
- Ocular Hypertension, Open Angle Glaucoma
- Interventions
- Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 489 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 30
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Garden Grove, California + 25 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- Ketotifen/naphazoline, Ketotifen, Naphazoline, Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- North Andover, Massachusetts
- Conditions
- Diabetes
- Interventions
- Thymosin Beta 4 (Tβ4), Placebo
- Drug · Other
- Lead sponsor
- ReGenTree, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 5
- States / cities
- Inglewood, California • Los Angeles, California • Orlando, Florida + 2 more